

May 1, 2018

Update: Commonwealth Diagnostics International, Inc. Re-Launches IBS*Schek*™ At Digestive Disease Week® (DDW) June 2018

First Clinically Validated Blood Test for Diagnosing Diarrhea-Predominant and Mixed-Type Irritable Bowel Syndrome

SALEM, MA May 1, 2018 - [Commonwealth Diagnostics International \(CDI\)](#), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of [IBS*Schek*™](#), the first clinically validated blood test for diarrhea-predominant and mixed-type [Irritable Bowel Syndrome](#) (IBS-D, IBS-M). CDI will officially re-launch IBS*Schek* to the gastroenterology community at Digestive Disease Week in Washington, DC in June 2018. CDI is a registered exhibitor at the Walter E. Washington Convention Center, Booth #919.

IBS*Schek* is a simple blood test that identifies the presence of two antibodies, anti-CdtB and anti-vinculin, which data have shown to be indicative of diarrhea-predominant IBS (IBS-D) and mixed-type IBS (IBS-M).¹ As a part of the re-launch, CDI has announced that the IBS*Schek* key biomarkers, anti-CdtB and anti-vinculin, are now included in the Rome Foundation's official Rome IV Clinical Decision Toolkit. Additionally, CDI continues to work with its medical advisory board, key opinion leaders, and leading healthcare institutions around the globe to conduct revalidation studies and clinical research projects aimed at further enhancing the clinical application and utility of these important biomarkers. CDI is also in the process of continuing to establish new commercial partnerships and distribution networks to assist in the expansion and scale of IBS*Schek* in the United States.

“We are excited to announce the availability of IBS*Schek*, and to continue to play our part in assisting the GI community to better-identify and treat the significant portion of the US and global population of IBS sufferers searching for a diagnosis,” said Craig S. Strasnick, President and CEO at CDI. “At CDI, we view new solutions such as IBS*Schek* as a representation of our unwavering commitment and dedication to providing innovative and cost-effective solutions to debilitating functional GI illness for our healthcare providers and their patients in the United States and around the world.”

In addition to the re-launch of IBS*Schek*, Commonwealth Diagnostics is also proud to announce the expansion of their test menu to include a serum-based ELISA test panel for Celiac Disease, which includes anti-human Tissue Transglutaminase (tTG) and deamidated gliadin peptide (DGP) IgA and IgG antibodies. This test is a valuable addition to the test portfolio due to the similar symptomology between Celiac and IBS patients, especially in the IBS subtypes of diarrhea predominant and mixed symptoms. “We believe that using both IBS*Schek* and the CDI Celiac Panel together will further direct clinicians towards the potential cause of their patients' symptoms, which may ultimately lead to a more effective course of treatment through a clearer diagnosis,” said Brianna Cassidy, PhD, Chief Science Officer at CDI. CDI will begin accepting diagnostic samples for Celiac testing in June 2018.

For more information about CDI, please visit our website at www.CommDx.com, or contact our customer service department at 888-258-5966.

References:

- 1) Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, et al. (2015) “Development and Validation of a biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects”. *PLoS ONE*. 2015;10: e0126438.
- 2) Rezaie A et al: Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. *Dig Dis Sci*. 2017;62:1480–1485.
- 3) Pourmorady J et al. The Utility of Measuring Anti-Cytolethal Distending Toxin B and AntiVinculin Antibodies in a Tertiary Care Motility Practice: A Free Range Experience. *Gastroenterology*. 2016; 4 (Suppl 1): S-230.
- 4) Schmulson M et al. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. *Rev Gastroenterol Mex*. 2016; 81:236-239.
- 5) Irritable bowel syndrome: symptoms. Mayo Clinic website. <http://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/basics/symptoms/con-20024578>. Accessed May 5, 2017.
- 6) Facts about IBS. International Foundation for Functional Gastrointestinal Disorders website. <http://www.aboutibs.org/facts-about-ibs.html>. Accessed May 5, 2017.
- 7) Gut bacteria and IBS. International Foundation for Functional Gastrointestinal Disorders website. <https://aboutibs.org/gut-bacteria-and-ibs.html>. Accessed July 12, 2017.